Related Experiment Videos
[Analysis of tumor rejection antigen peptides recognized by specific CTL]
1Department of Parasitology and Immunology, Okayama University Medical School.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 1, 1996
Summary
Tumor rejection antigens are recognized by cytotoxic T lymphocytes (CTL). Analyzing these tumor antigens, like MAGE-1/3 and tyrosinase in melanoma, aids in developing effective tumor vaccines.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumor rejection antigens are crucial targets for cytotoxic T lymphocytes (CTLs) in cancer immunity.
- Specific antigen peptides recognized by CTLs have been identified in various human and murine tumors.
Purpose of the Study:
- To identify and characterize tumor rejection antigen peptides.
- To elucidate the molecular basis of tumor rejection antigens.
- To facilitate the therapeutic application of tumor antigens in vaccine development.
Main Methods:
- Identification of tumor antigen peptides through immunological assays.
- Analysis of molecular characteristics of identified antigen peptides.
- Characterization of T cell responses against tumor antigens.
Main Results:
- MAGE-1 and MAGE-3 antigen peptides recognized by CTLs were defined in malignant melanoma.
- Tyrosinase, gp100, and Melan A/MART-1, melanosome-associated proteins, are recognized by specific CTLs.
- P1A, MUT1, and pRL1 were identified as antigenic peptides in murine tumors.
Conclusions:
- Analysis of tumor rejection antigen peptides provides insights into their molecular nature.
- Understanding these antigens is key to developing effective tumor vaccines for cancer therapy.